Zhejiang Haisen Pharmaceutical Co., Ltd. (SHE:001367)
China flag China · Delayed Price · Currency is CNY
25.92
-0.50 (-1.89%)
At close: Apr 15, 2026

SHE:001367 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
531.67470.54396.28421.14386.79
Other Revenue
0.590.971.171.642.19
532.26471.51397.45422.78388.98
Revenue Growth (YoY)
12.88%18.63%-5.99%8.69%36.58%
Cost of Revenue
291.24281.91237.4266.52236.12
Gross Profit
241.02189.6160.05156.26152.87
Selling, General & Admin
52.2440.6535.7232.2532.94
Research & Development
38.8627.7818.8415.7712.07
Other Operating Expenses
4.584.364.162.133.11
Operating Expenses
98.4172.8859.1551.2447.85
Operating Income
142.61116.72100.9105.02105.02
Interest Expense
-0.35-0.37-0.03-0.07-0.1
Interest & Investment Income
10.718.4115.623.552.25
Currency Exchange Gain (Loss)
-0.053.320.878.37-2.17
Other Non Operating Income (Expenses)
-0.28-0.24-0.190.05-0.4
EBT Excluding Unusual Items
152.62137.85117.17116.93104.59
Gain (Loss) on Sale of Investments
1.7---3.850.74
Gain (Loss) on Sale of Assets
---0.24--
Asset Writedown
-0.4-1.23-0.96-1.21-0.67
Other Unusual Items
2.845.114.7111.913.86
Pretax Income
156.76141.79120.68123.78108.52
Income Tax Expense
20.8819.2316.0116.1914.52
Net Income
135.88122.56104.67107.5994
Net Income to Common
135.88122.56104.67107.5994
Net Income Growth
10.87%17.09%-2.72%14.46%49.62%
Shares Outstanding (Basic)
149149137112112
Shares Outstanding (Diluted)
153149137112112
Shares Change (YoY)
2.15%9.03%22.74%-0.02%-
EPS (Basic)
0.910.820.760.960.84
EPS (Diluted)
0.890.820.760.960.84
EPS Growth
8.54%7.40%-20.74%14.68%49.60%
Free Cash Flow
25.19102.4123.1754.7673.72
Free Cash Flow Per Share
0.170.690.170.490.66
Dividend Per Share
0.1160.1700.228--
Dividend Growth
-31.77%-25.50%---
Gross Margin
45.28%40.21%40.27%36.96%39.30%
Operating Margin
26.79%24.75%25.39%24.84%27.00%
Profit Margin
25.53%25.99%26.33%25.45%24.16%
Free Cash Flow Margin
4.73%21.72%5.83%12.95%18.95%
EBITDA
164.28132.04113.52118.59117.37
EBITDA Margin
30.87%28.00%28.56%28.05%30.17%
D&A For EBITDA
21.6815.3212.6213.5612.35
EBIT
142.61116.72100.9105.02105.02
EBIT Margin
26.79%24.75%25.39%24.84%27.00%
Effective Tax Rate
13.32%13.56%13.26%13.08%13.38%
Revenue as Reported
532.26471.51397.45422.78388.98
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.